Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 2/20 | 0.44 |
| ▸ | CCND1 | P24385 | 2/20 | 0.44 |
| ▸ | CCND2 | P30279 | 2/20 | 0.44 |
| ▸ | CCND3 | P30281 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 4/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.38 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9310207 | 0.81 | BTK (0.52) | KDM4EALDH1A1GAAKMT2ACDK4 | |
| SCHEMBL30798989 | 0.79 | BTK (0.42) | KDM4EALDH1A1GAAKMT2ACDK4 | |
| SCHEMBL17576257 | 0.79 | BRPF1 (0.62) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL9367980 | 0.79 | BTK (0.42) | KDM4EALDH1A1GAAKMT2ACDK4 | |
| SCHEMBL9161052 | 0.78 | KMT2A (0.52) | KDM4EMEN1ALDH1A1GAAKMT2A | |
| SCHEMBL4049057 | 0.77 | GRIK1 (0.55) | KDM4EKMT2ASMN1; SMN2CDK4CCND1 | |
| SCHEMBL9124674 | 0.77 | ALOX5 (0.42) | KDM4EALDH1A1GAAKMT2ACDK4 | |
| SCHEMBL1238373 | 0.77 | BRPF1 (0.62) | EGFRBRPF1 | |
| SCHEMBL19495463 | 0.76 | MAPK9 (0.45) | BTK | |
| SCHEMBL17576256 | 0.74 | CYP1A2 (0.61) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED | 2009-10-01 | — | — | US | disclosed |
| EP-2029584-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | Cancer Research Technology Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096618-A2 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247579-A1 | 2-[3H-THIAZOL-2-YLIDINEMETHYL]PYRIDINES AND RELATED COMPOUNDS AND THEIR USE | RB1, RBBP5, RRM2B | KDM4E 260/4885MEN1 2905/4885ALDH1A1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.